Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 20 Carcinoma, Non-Small-Cell Lung 18 Esophageal Squamous Cell Carcinoma 15 Breast Neoplasms 14 Triple Negative Breast Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 11 Carcinoma, Hepatocellular 11 Stomach Neoplasms 8 Small Cell Lung Carcinoma 8 Uterine Cervical Neoplasms 6 Recurrence 6 Head and Neck Neoplasms 6 Colorectal Neoplasms 6 Carcinoma, Transitional Cell 5 Carcinoma, Renal Cell 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Rectal Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Locally Advanced Rectal Cancer 3 Liver Neoplasms 3 Turcot syndrome 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Neoplasms 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × toripalimab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡